5-FU, a MDM2 inhibitor, aBcl-2 inhibitor, Abraxane, Paclitaxel, Gemcitabine, Bortezomib, Cyclopamine, a PARP inhibitor, Ifosfamide or an anti-VEGF antibody.

42. The method of claim 41, wherein the medicament is for treatment of colorectal cancer, sarcoma, head and neck cancers, squamous cell carcinomas**, breast cancer**, pancreatic cancer, gastric cancer, non-small-cell lung carcinoma, small-cell lung cancer and mesothelioma.

43. The method of claim 42, wherein the sarcoma is chondrosarcoma, leiomyosarcoma, gastrointestinal stromal tumours, fibrosarcoma, osteosarcoma. liposarcoma or maligant fibrous histiocytoma.